Retatrutide
LY3437943 (triple agonist)
Retatrutide is an investigational <b>triple hormone-receptor agonist</b> — it activates GIP, GLP-1 and glucagon receptors at once, making it the most ambitious incretin drug in late-stage development. In 2026 Phase 3 TRIUMPH trials it produced some of the largest weight-loss numbers ever reported for a medication. This guide covers how retatrutide works, what the trials showed, where it stands in development, safety, and how it compares to semaglutide and tirzepatide. Retatrutide is not yet approved — this is educational information, not medical advice.
Retatrutide quick facts
| Reported research dosing (Injectable) | 0.5mg-12mg |
| Route | Subq |
| Cycle length | As Long As Needed |
| Frequency | 1-2x Weekly (Split Dose) |
| Half-life | ~6 days |
| Forms | Injectable |
| Evidence level | Phase 2 human (strong; ~24% weight loss) |
| Other forms available | Oral — dosed differently |
The most exciting fat-loss compound out right now. Titrate slowly — side effects track with jumping dose too fast.
How retatrutide works
Retatrutide is a single once-weekly molecule that activates three receptors: GLP-1 (appetite, gastric emptying, insulin), GIP (insulin-sensitizing, metabolic), and — the differentiator — glucagon. The glucagon arm is thought to increase energy expenditure and drive hepatic (liver) fat loss on top of the appetite suppression the other two provide. Hitting all three incretin/metabolic pathways is the theory behind its outsized effect.
What the research shows
The Phase 3 TRIUMPH program has delivered striking numbers. TRIUMPH-2 (reported January 2026) showed a ~24.2% mean body-weight reduction at 72 weeks on the 12 mg dose versus 2.1% for placebo; TRIUMPH-4 reported ~28.7% at 68 weeks on 12 mg in a population with obesity and knee osteoarthritis; and TRIUMPH-1 met its primary obesity endpoints across 4, 9 and 12 mg doses at 80 weeks. In type 2 diabetes (TRANSCEND-T2D-1), it delivered A1C reductions up to ~2.0% with meaningful weight loss. Several more Phase 3 readouts were expected through 2026.
Where retatrutide stands (development status)
Crucially, retatrutide is investigational — not yet FDA-approved. It is being developed by Eli Lilly and, as of 2026, is completing its Phase 3 program ahead of any regulatory submission. That means there is no approved retatrutide product, no approved dosing, and the long-term safety picture is still being built. Anything sold as 'retatrutide' outside a clinical trial is unapproved.
Safety & what's still unknown
In trials the side-effect profile has looked like the incretin class — predominantly gastrointestinal (nausea, vomiting, diarrhea), most pronounced during dose escalation. Because it adds glucagon-receptor activity, researchers are watching effects on heart rate and glucose closely. The honest bottom line: retatrutide is promising but unproven long-term, and its full safety profile won't be clear until the Phase 3 program and regulatory review are complete.
Retatrutide vs semaglutide vs tirzepatide
This is the three-generation story of incretin therapy. Semaglutide hits one pathway (~15–21%). Tirzepatide hits two (~20–22.5%). Retatrutide hits three and has shown ~24–30% in trials — the largest of the group. But it's also the least mature: semaglutide and tirzepatide are FDA-approved with years of real-world data, while retatrutide is still investigational.
Important safety & legal note
Because retatrutide is not approved, there is no legitimate prescription pathway outside a clinical trial, and any product marketed as retatrutide is unapproved and unregulated. The FDA has broadly warned about unapproved GLP-1-class products. This page is educational only and is not a recommendation to obtain or use retatrutide.
Where to get Retatrutide
Retatrutide is sold in 2 forms. They are not interchangeable — the dose and the route differ, so pick the one this page describes unless you know why you want another.
Retatrutide reconstitution calculator
Research reconstitution calculator
Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for Retatrutide
Graded by what exists behind each claim.
✅ Clinically validated
- Phase 2 produced the largest weight loss recorded for any drug in a randomized trial — 24.2% at 48 weeks at the 12 mg dose, with the curve still falling at the end of the study. Phase 3 has read out: TRIUMPH-4 (11 Dec 2025), TRIUMPH-1 (21 May 2026), and TRIUMPH-2 and TRIUMPH-3 (23 Jul 2026).
- Lilly plans to file with the FDA in Q1 2027. It isn't approved anywhere.
📊 Correlative data
- Widely used ahead of approval through research channels. Reported experience tracks the trial — very strong appetite suppression, and a noticeably higher rate of the heart-rate increase seen in the published data.
- Beyond that the record is self-reported: community dosing logs are real information about tolerability and almost none about efficacy.
🧪 Theoretical / extrapolated
- A triple agonist: GLP-1, GIP and glucagon. The glucagon arm is the novel part and the reason for the effect size — glucagon receptor agonism raises energy expenditure rather than only reducing intake, so this attacks both sides of the balance where the dual and single agonists attack one.
- The same glucagon activity predicts the two things to watch: raised heart rate, and effects on hepatic glucose output that make it less predictable in someone with unstable glycemic control.
What community dosing logs are worth →
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Retatrutide actually does
Retatrutide is one molecule that has to satisfy three different receptors, and two of them pull in opposite directions. It is a single-chain peptide agonist at the GIP, GLP-1 and glucagon receptors Jastreboff 2023. Glucagon receptor agonism raises hepatic glucose output. GLP-1 receptor agonism lowers blood glucose. Building both into one molecule is deliberate, and the reason is energy expenditure.
Why anyone would add a glucagon agonist on purpose. The glucagon receptor is a class B GPCR concentrated in hepatocytes. Beyond glycogenolysis and gluconeogenesis it drives hepatic fatty acid oxidation and raises resting energy expenditure. A pure GLP-1 agonist reduces energy intake; adding glucagon agonism attacks the other side of the balance. The engineering problem is that the same receptor raises blood glucose, so the GLP-1 arm has to be strong enough to cover the glucagon arm at every dose. This is the same design logic as the dual GCGR/GLP-1R agonists Thomas 2024 and it is why the ratio between the arms, not the total potency, is the property that gets optimized.
What the GIP arm is doing, which is the genuinely contested part. Glucose-dependent insulinotropic polypeptide acts on the beta cell to potentiate insulin release and on adipocytes, where its classical role is to promote lipid storage. That makes GIP agonism in a fat-loss drug counterintuitive — and a credible school of thought holds that chronic GIP receptor agonism produces functional receptor desensitization, so a sustained agonist behaves in the tissue like an antagonist. Nobody has settled this, and it is the sharpest open question in the incretin field. Tirzepatide, the approved GIP/GLP-1 dual agonist, has the same unresolved argument attached to it Urva 2021.
The structural trick is the same one semaglutide uses. Retatrutide carries a fatty-acid modification for albumin binding, which is what makes weekly dosing possible; the card's ~6-day half-life is a property of that albumin association rather than of peptide stability.
Cell, rodent, human — and where it stops
Step one, phase 2 in obesity, and the number is the largest in the class. Jastreboff 2023 randomized 338 adults (51.8% male). At 24 weeks the mean change in body weight was −17.5% in the 12 mg group against −1.6% on placebo. That is a phase 2 endpoint at 24 weeks under trial supervision with a fixed escalation, not a target and not a prediction for anybody. Gastrointestinal adverse events were the commonest, were dose-related, and were mostly mild to moderate.
Step two, the liver, where the glucagon arm should show itself. Sanyal 2024 ran a randomized phase 2a trial in 98 participants with metabolic dysfunction-associated steatotic liver disease. Mean relative change in liver fat at 24 weeks was −42.9% at 1 mg, −57.0% at 4 mg, −81.4% at 8 mg and −82.4% at 12 mg against +0.3% on placebo, all P<0.001 versus placebo. This is the mechanistic result, not the cosmetic one: a clean dose-response in the organ the glucagon receptor is concentrated in, with a plateau between 8 and 12 mg that says the hepatic effect saturates before the top dose.
Step three, type 2 diabetes. A phase trial in people with type 2 diabetes has since reported Bajaj 2026, which is the population where the glucagon arm's glucose-raising tendency is most dangerous and therefore the population that tests the design.
Step four, the pooled picture. A meta-analysis covering 640 patients, 510 of them on retatrutide, reports a weighted mean difference in body weight of −10.66 kg (95% CI −17.63 to −3.69) and a relative risk of 9.32 (95% CI 4.56–19.06) for reaching the trials' own 10% threshold Pasqualotto 2024. Read the confidence interval, not the point estimate: −17.63 to −3.69 kg is a very wide band, and it is wide because the underlying evidence is a handful of phase 2 trials at different doses.
Where the chain breaks. (1) There is no phase 3 outcome trial. Semaglutide has SELECT, with 17,604 people and a hard cardiovascular endpoint Lincoff 2023; retatrutide has nothing of the kind, and until it does, the comparison between them is a comparison between a surrogate and an outcome. (2) 338 people for 24 weeks cannot detect an uncommon harm. (3) The glucagon arm's long-term effect on hepatic glucose production in a non-trial population is unmeasured. (4) Every gram of material outside a trial is research-grade peptide of unverified identity, which is a different question from whether the molecule works.
What would have to be true, and how you would know it was not
Three predictions, and the first two are the ones that separate this molecule from a GLP-1 agonist.
1. If the glucagon arm is doing what it is designed to do, the liver moves further than the scale does. The phase 2a liver-fat result is an 81% relative reduction at 8 mg against a 17.5% weight change at 12 mg in the obesity trial Sanyal 2024 Jastreboff 2023. So the read-out is hepatic: ALT and GGT on a CMP at baseline and 12 weeks, and if it is available, a FibroScan controlled attenuation parameter at baseline and six months. If liver fat does not move, the glucagon arm is not engaged, whatever the scale says.
2. The falsification test is glycemic, and it runs the wrong way. Glucagon receptor agonism raises hepatic glucose output. If the GLP-1 arm is under-dosed relative to it — a real possibility with material of unverified content — then fasting glucose and HbA1c should rise, not fall. A CMP and HbA1c at baseline and 12 weeks catch that. A person watching only the scale would miss it entirely, and it is the most specific way this molecule can go wrong.
3. Heart rate, because the class raises it and the third receptor may raise it more. Resting heart-rate increase is a labeled warning for semaglutide Wegovy label 2026, and glucagon receptor agonism has its own chronotropic effect. Two weeks of morning resting heart rate before starting and the same measurement monthly afterward is free. A sustained rise of more than about ten beats per minute is a reason to stop and ask, not a reason to continue and hope.
What nobody has tested yet
Four experiments nobody has run, and the first one is the whole argument.
Nobody has tested whether the GIP arm helps. The molecule hits three receptors; no published trial compares retatrutide against an otherwise identical GLP-1/glucagon dual agonist. Until that comparison exists, the GIP arm is a hypothesis with a manufacturing cost attached, and the agonist-versus-desensitization argument above cannot be settled by any amount of clinical weight data.
Nobody has run a cardiovascular outcome trial. The glucagon arm raises energy expenditure and heart rate. That is a combination with a specific historical failure mode, and only a long randomized trial with adjudicated events can say whether it applies. Retatrutide's entire published record is surrogate endpoints.
Nobody has published the effect on lean mass with an imaging endpoint at the top dose. The question is being taken seriously enough elsewhere in the class that a bimagrumab combination trial has been run Heymsfield 2026; the equivalent for a triple agonist does not exist.
Nobody has tested the liver plateau. Liver fat fell 81.4% at 8 mg and 82.4% at 12 mg Sanyal 2024. If the hepatic effect is saturated at 8 mg while the adverse-event rate keeps climbing with dose, then the top dose buys nothing for the liver. A dose-ranging trial with the hepatic endpoint as primary would answer that, and it would be the most useful trial anybody could run on this molecule.
Retatrutide — its own safety story, not its class's
Retatrutide is not approved anywhere. That single fact changes the shape of everything below, and it is the reason the class block above does not fit.
There is no label, so there is no boxed warning — and that is not reassurance. Semaglutide's boxed warning for thyroid C-cell tumors Wegovy label 2026 exists because rodent carcinogenicity studies were done and reviewed. For retatrutide, the equivalent review has not been published. Absence of a warning on an unapproved molecule means nobody has finished looking, which is the opposite of what it looks like.
The glucagon arm is the specific hazard this molecule has that the others do not. Hepatic glucose output rises with glucagon receptor agonism. In a trial the GLP-1 arm covers it, at a ratio fixed by the manufacturer. In material of unverified identity and unverified concentration, that ratio is an assumption. The failure mode is hyperglycemia in somebody who believes they are taking a glucose-lowering drug.
The gastrointestinal profile is dose-related and was the commonest adverse event in the phase 2 trial Jastreboff 2023. The class hazards that carry labels elsewhere — pancreatitis, gallbladder disease, delayed gastric emptying and its anesthetic implications Wegovy label 2026, gallbladder signal in class-wide data He 2022 — have no reason not to apply to a molecule with a GLP-1 arm, and no trial large enough to quantify them.
What this page will not do. Suggest a dose, a source, or a schedule. The trial numbers above are 24-week phase 2 endpoints in supervised participants; they are what the molecule did in a trial, not what it will do to a reader, and the honest summary of retatrutide in September 2026 is a well-designed molecule with a striking liver result and no outcome data at all.
Sources read for this page
- Pasqualotto E, et al. Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers. Metabolism Open 2024 · PMID 39318607
Retatrutide — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These slow gastric emptying and act on hypothalamic and brainstem appetite centers. Almost everything that goes wrong follows from the gastric emptying, not from anything exotic: nausea, early fullness, reflux, constipation, and — when someone titrates faster than their gut adapts — vomiting.
- The composition risk is the one nobody warns about. Appetite suppression does not discriminate. It suppresses the appetite for protein too, and in a deficit without adequate protein and a resistance stimulus a meaningful share of the loss is lean mass. That lowers the maintenance intake you eventually eat back into, which is the mechanism behind most of the rebound stories.
- Slowed emptying also delays absorption of anything else taken by mouth — a pharmacokinetic consequence rather than a drug interaction, but it matters for anything time-critical.
What has actually been reported
- GI effects are extremely common and mostly settle over weeks. Gallbladder problems are a recognized signal, and rapid weight loss of any cause raises gallstone risk — the drug is not doing something unusual, it is doing rapid weight loss well.
- Pancreatitis is reported and rare. The presentation to know is severe upper abdominal pain radiating to the back, usually with vomiting.
- A thyroid C-cell tumor signal exists in rodents and has not been demonstrated in humans; it is why the labeled contraindication for medullary thyroid carcinoma and MEN2 exists.
How to reduce the risk
Same mechanism as the prediction.
- Follow the titration schedule even if you feel fine. It exists for gut adaptation, not for legal cover. Almost everyone who quits in the first month escalated faster than their stomach could keep up.
- Hit your protein target first at every meal, before anything else on the plate. This is the single highest-leverage habit on the drug — 1.6–2.2 g/kg, and eat it while you still have the appetite to.
- Lift while you are on it. The compound handles intake; resistance training is the only thing handling what you keep.
- Aim for 0.5–1% of bodyweight per week, deliberately. The drug removes the hunger signal that would normally stop you going too hard, so the rate has to be a decision rather than a by-product.
- Fiber and electrolytes from day one, not from week four when constipation has already made up your mind about the drug.
- If nausea is winning, step back one dose rather than quitting the class. Almost nobody needs to be at the top of the range.
What it does to your bloodwork
A fact about the assay.
- HbA1c and fasting glucose should improve — that is the drug working, and it is the cleanest confirmation you have.
- Rapid loss moves lipids, liver enzymes and uric acid transiently. A wobble at 8 weeks into aggressive loss is usually the loss, not a new problem — but it is a reason to have the baseline.
- Worth a thyroid panel and a lipid panel before starting, simply so a later result has something to be compared against.
Don't run this if
- Personal or family history of medullary thyroid carcinoma, or MEN2.
- Previous pancreatitis.
- Active gastroparesis — you would be adding a drug whose main action is the thing already wrong.
The honest unknown
- What happens to body composition over repeated multi-year cycles of loss and regain on and off these drugs. Weight is well studied; the muscle-to-fat ratio of what comes back is not.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Any time — but the same day each week
With a half-life measured in days you are dosing into a standing level, so the hour is irrelevant and the consistency is not. Pick a day and hold it; drifting the interval is what produces the peaks and troughs people mistake for the drug not working.
Food makes no meaningful difference at this half-life.
From half-life and route, not a dosing trial.
Retatrutide — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Retatrutide moves on your bloodwork
Expected direction, not a measured one.
- HbA1c (Hemoglobin A1c) — ↓ expected to fall
Falling HbA1c is the compound working. Expect it.
What to do: Baseline and 12 weeks. It moves slowly by design — a 4-week retest tells you very little. - Fasting Insulin — ↓ expected to fall
Insulin sensitivity improves as weight falls and the incretin effect restores first-phase insulin release.
What to do: Useful alongside HbA1c; the two together read the trend properly. - Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) — ↓ expected to fall
Triglycerides in particular fall with weight loss and improved insulin sensitivity.
What to do: Re-check at 12 weeks rather than chasing early numbers. - Lipase — ↑ expected to rise
Lipase and amylase can rise without pancreatitis on this class. An isolated mild elevation in someone with no symptoms is common.
What to do: Severe, persistent abdominal pain radiating to the back is the thing that matters, not the number. Symptoms decide, not a mild enzyme rise. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Rapid weight loss and reduced intake shift electrolytes and kidney markers; dehydration from nausea or vomiting shows up here first.
What to do: Worth a baseline. If you have been vomiting, this is the panel that catches the consequence. - Ferritin — ↓ expected to fall
Not the drug — the eating. Sharply reduced intake drops iron, B12 and protein intake with it, and this is the most commonly missed consequence of a good response.
What to do: Check ferritin and B12 at 12 weeks. Muscle loss and hair shedding on a GLP-1 is very often a nutrition problem wearing a drug's name.
The pattern with this class is that the frightening-looking numbers (lipase) are usually fine and the boring ones (ferritin, B12) are where the real damage happens.
Everything on this page, in an order
This one is free and stays free. What Skool adds is the rest of the shelf — 278 compounds and 371 supplements with the protocol, the stack order and the bloodwork to run beside it.
Join Skool — $10/mo →Bloodwork to run alongside Retatrutide
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| HbA1c (Hemoglobin A1c) | Baseline before the most potent agent in the class |
| Fasting Insulin | The earliest marker of the metabolic change |
| Lipase | Pancreatitis monitoring, as with every incretin |
| Comprehensive Metabolic Panel (CMP) | Liver, kidney and electrolytes |
The “On a GLP-1 (Semaglutide / Tirzepatide)” panel covers these in one order — 11 markers, $148.05 with the discount applied.
Check results you already have → · All 103 markers A–Z
Retatrutide — frequently asked questions
What is retatrutide?
Retatrutide is an investigational once-weekly triple agonist that activates GIP, GLP-1 and glucagon receptors. It's being developed by Eli Lilly and is not yet FDA-approved.
How does retatrutide work?
It activates three pathways at once: GLP-1 and GIP (appetite, insulin, metabolic effects) plus glucagon, which is thought to raise energy expenditure and reduce liver fat — the combination behind its large trial effects.
How much weight can you lose on retatrutide?
In Phase 3 TRIUMPH trials, the 12 mg dose produced roughly 24–29% average weight loss depending on the study and population — among the highest reported for a medication. It remains investigational and results vary.
Is retatrutide FDA-approved?
No. As of 2026 retatrutide is still investigational and completing its Phase 3 program. There is no approved product, no approved dosing, and anything sold as retatrutide outside a trial is unapproved.
Retatrutide vs tirzepatide vs semaglutide?
Semaglutide targets one pathway, tirzepatide two, retatrutide three. Retatrutide has shown the largest trial weight loss (~24–30%) but is the least mature — the other two are FDA-approved with more long-term data.
What are the side effects of retatrutide?
In trials, mostly GI effects (nausea, vomiting, diarrhea), worst during dose escalation. Because it adds glucagon activity, heart rate and glucose are being watched closely. Long-term safety is still being established.
References & further reading
- Lilly: retatrutide Phase 3 obesity trial results (investor release)
- Retatrutide up to 30.3% average weight loss in Phase 3 TRIUMPH-1 (AJMC)
- FDA: concerns with unapproved GLP-1 drugs used for weight loss
Retatrutide inside a finished plan
One arm of 2 Protocol Blueprints, free to read in full.
What Retatrutide is used for
Retatrutide appears under 2 goals in the goal router.
Related Metabolic & Fat Loss compounds
Where this goes next
Retatrutide is the appetite arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.